Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 GLOBAL HYOSCINE MARKET, BY TYPE

4.1. OVERVIEW

4.1.1. Key market trends
4.1.2. Key growth factors and opportunities
4.1.3. Market size and forecast

4.2. HYOSCINE BUTYLBROMIDE

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. HYOSCINE HYDROBROMIDE

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

Chapter: 5 GLOBAL HYOSCINE MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2.  ORAL

5.2.1. Key market trends
5.2.2. Growth factors and opportunities
5.2.3. Market size and forecast

5.3. INJECTIONS

5.3.1. Key market trends
5.3.2. Growth factors and opportunities
5.3.3. Market size and forecast

5.4. PATCHES

5.4.1. Key market trends
5.4.2. Growth factors and opportunities
5.4.3. Market size and forecast

Chapter: 6 GLOBAL HYOSCINE MARKET, BY GEOGRAPHY

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. By Type
6.2.3.2. By Application

6.2.4. U.S.

6.2.4.1. Market size and forecast, by Application

6.2.5. Canada

6.2.5.1. Market size and forecast, by Application

6.2.6. Mexico

6.2.6.1. Market size and forecast, by Application

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. By Type
6.3.3.2. By Application

6.3.4. UK

6.3.4.1. Market size and forecast, by Application

6.3.5. Germany

6.3.5.1. Market size and forecast, by Application

6.3.6. France

6.3.6.1. Market size and forecast, by Application

6.3.7. Spain

6.3.7.1. Market size and forecast, by Application

6.3.8. Italy

6.3.8.1. Market size and forecast, by Application

6.3.9. Rest of Europe

6.3.9.1. Market size and forecast, by Application

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. By Type
6.4.3.2. By Application

6.4.4. China

6.4.4.1. Market size and forecast, by Application

6.4.5. Japan

6.4.5.1. Market size and forecast, by Application

6.4.6. India

6.4.6.1. Market size and forecast, by Application

6.4.7. Australia

6.4.7.1. Market size and forecast, by Application

6.4.8. South Korea

6.4.8.1. Market size and forecast, by Application

6.4.9. Rest of Asia-Pacific

6.4.9.1. Market size and forecast, by Application

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. By Type
6.5.3.2. By Application

6.5.4. Brazil

6.5.4.1. Market size and forecast, by Application

6.5.5. South Africa

6.5.5.1. Market size and forecast, by Application

6.5.6. Saudi Arabia

6.5.6.1. Market size and forecast, by Application

6.5.7. Rest of LAMEA

6.5.7.1. Market size and forecast, by Application

Chapter: 7 COMPANY PROFILES

7.1. ALCHEM INTERNATIONAL LTD.

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. ALKALOIDS CORPORATION

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. BAXTER INTERNATIONAL INC.

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. CALEB PHARMACEUTICALS, INC.

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. CENTROFLORA CMS S.À R.L.

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. GLAXOSMITHKLINE PLC

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. GUANGZHOU HANFANG PHARMACEUTICAL CO., LTD.

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. MYUNGMOON PHARMA CO., LTD.

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. NOVARTIS INTERNATIONAL AG

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. PERRIGO COMPANY PLC

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments